Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Egrifta Approval Suggests Evolution In FDA Thinking On Role Of REMS

Nov 29 2010

• By Sue Sutter

Related Content

<i>Egrifta</i> Post-marketing Study On Diabetic Retinopathy Will Include CV Outcomes

Nov 22 2010

Delayed Egrifta Approval Brings Clean Label, No REMS For Theratechnologies

Nov 11 2010

“Defensive REMS” May Be Needed To Appease Advisory Committees

Nov 29 2010

Early REMS Assessments Show Room For Improvement In MedGuides

Nov 29 2010

REMS Templates Get Nod From FDA, With Nudge From Pharmacists

Jul 28 2010

Egrifta Quality Of Life Deciding Factor In Advisory Panel's Recommendation

May 31 2010

FDA Seeks To Write MedGuides Outside REMS Process

Jun 21 2010

Additional Topics

BioPharmaceutical

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window